Matinas BioPharma Holdings IncMatinas is selling its core assets and merging into a clean energy company, causing a sharp stock decline.

Matinas BioPharma Holdings has announced a merger with GH Power to form a publicly traded clean energy and green hydrogen company, while separately selling its lipid nano-crystal technology and antifungal candidate MAT2203 to Azurity Pharmaceuticals. Under the merger, the combined entity will be called GH Power International and list on the NYSE, focusing on advanced clean energy solutions using proprietary modular reactors that convert scrap metals and water into high-purity alumina, clean hydrogen, and thermal energy. The sale to Azurity includes a $4 million upfront payment, up to $17.5 million in milestone payments, and future mid-single-digit royalties. The dual transaction marks a strategic pivot for Matinas from biopharmaceutical development to clean energy and critical materials. Matinas shares closed Monday at $0.48, down 36.45%, and fell a further 16.04% in overnight trading to $0.40.
Matinas BioPharma Holdings IncMatinas is selling its core assets and merging into a clean energy company, causing a sharp stock decline.
GH Power merges with Matinas to become a publicly traded clean energy company, gaining access to capital markets.
Azurity acquires LNC platform and MAT2203, gaining a novel drug delivery technology and antifungal candidate.